# The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Study · id `cardio:ct-nct04912167` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04912167](<https://clinicaltrials.gov/study/NCT04912167>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04912167

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 376 participants.

## Technical summary

Registry record NCT04912167. Randomized; single masking; primary purpose treatment. Start 2021-11 (anticipated); primary completion 2022-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 376 participants (planned count; ClinicalTrials.gov record NCT04912167, source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)
- Planned start: 2021-11 (anticipated) (ClinicalTrials.gov record NCT04912167, source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)
- Primary completion: 2022-03 (anticipated) (ClinicalTrials.gov record NCT04912167, source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)
- Completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT04912167, source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04912167, source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04912167-2021-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
- Acronym: PERI-STEMI
- Condition: STEMI
- Intervention (Drug): Sacubitril-Valsartan
- Intervention (Drug): Enalapril
- Intervention (Drug): Valsartan
- Lead sponsor: West China Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: West China Hospital (`cardio:org-west-china-hospital`)

## Provenance

Content hash: a3334b7001bf7b9ed0ccb9d5c6239775680153db47f41868b2ec8e34891b17d1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
